Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Galera Therapeutics ( (GRTX) ).
Galera Therapeutics has completed the acquisition of Nova Pharmaceuticals, which focuses on developing a pan-NOS inhibitor to treat resistant forms of breast cancer. The merger shifts Galera’s strategy towards anti-cancer therapeutics, with plans for multiple clinical trials, including a Phase 1/2 trial for metaplastic breast cancer. This acquisition is expected to bolster Galera’s financial and operational capabilities, with support from investors and strategic partnerships to fund developments through 2026.
More about Galera Therapeutics
Galera Therapeutics, Inc. is a biopharmaceutical company that develops small molecule superoxide dismutase mimetics. Historically, it has focused on reducing the toxicities of chemoradiotherapy regimens in patients with head and neck cancer. The company has received FDA Fast Track and Breakthrough Therapy designations for avasopasem, aimed at reducing severe oral mucositis induced by radiotherapy.
YTD Price Performance: -81.38%
Average Trading Volume: 141,052
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.47M
Learn more about GRTX stock on TipRanks’ Stock Analysis page.
